Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan, Sintilimab, and Anlotinib in Recurrent Ovarian Clear Cell Carcinoma
NCT07239622Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, sintilimab, anlotinib in ovarian clear cell carcinoma (OCCC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecansintilimabanlotinib
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT07239622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239622.